Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SCTX

Scribe Therapeutics Inc

26.00

Aug 07 • 3:59 PM ET +0.59 (2.32%)

26.00

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: IPSC PRME CMPX PRLD BEAM NTLA LXEO RCKT CRSP ABEO

| Held by: ARKG HLTH

Scroll to Statements

Index	-
Market Cap	420.73M
Enterprise Value	537.69M
Income	-
Sales	-
Book/sh	-9.03
Cash/sh	3.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	8.46
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.66
Current Ratio	0.66
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	36.14%
Insider Trans	423.13%
Inst Own	30.23%
Inst Trans	13.15%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	21.69%
SMA50	21.69%
SMA200	21.69%
Trades

Shs Outstand	17.58M
Shs Float	10.33M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	26.25 -0.95%
52W Low	17.31 50.25%
Volatility	11.56% -
ATR (14)	2.93
RSI (14)	-
Beta	-
Rel Volume	0.38
Avg Volume	312.18K
Volume	120,180

Perf Week	33.47%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	4.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	25.41
Price	26.00
Change %	2.32%

Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-FounderDr. Benjamin L. Oakes Ph.D.

CFO & TreasurerMr. David L. Parrot M.B.A.

Chief Business OfficerDr. Svetlana Lucas Ph.D.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund II, L.P.	10% Owner	Jul 27 '26	Buy	15.00	333,333	4,999,995	2,385,075	Jul 29 07:09 PM
GORDON CARL L	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:50 PM
ORBIMED ADVISORS LLC	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:47 PM
Aghazadeh Behzad	Director	Jul 24 '26	Buy	15.15	2,383,333	36,115,495	3,080,983	Jul 28 09:30 PM
Aghazadeh Behzad	Director	Jul 28 '26	Buy	18.25	7,905	144,266	3,088,888	Jul 28 09:30 PM
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCTX

Scribe Therapeutics Inc

Upgrade your Finviz experience